scholarly article | Q13442814 |
P50 | author | Thomas Ten Have | Q57327797 |
Matthew B. Stern | Q67208124 | ||
P2093 | author name string | H. I. Hurtig | |
T. R. Ten Have | |||
D. Weintraub | |||
A. Colcher | |||
J. E. Duda | |||
S. Mavandadi | |||
E. Mamikonyan | |||
A. D. Siderowf | |||
S. S. Horn | |||
S. Nazem | |||
P2860 | cites work | Acta Neurologica Scandinavica | Q4676732 |
Primary versus secondary insomnia in older adults: subjective sleep and daytime functioning | Q48691209 | ||
Reliability, validity, and clinical correlates of apathy in Parkinson's disease | Q48852465 | ||
Depression and disability in Parkinson's disease. | Q51003628 | ||
Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. | Q51974389 | ||
Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. | Q52015908 | ||
Augmentation With Open-Label Atomoxetine for Partial or Nonresponse to Antidepressants | Q56386964 | ||
9/Geriatric Depression Scale (GDS) | Q56780750 | ||
Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA | Q64791376 | ||
Recognition and treatment of depression in Parkinson's disease | Q73926182 | ||
Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans | Q24654140 | ||
“Mini-mental state” | Q25938989 | ||
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale | Q28256570 | ||
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice | Q29614979 | ||
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease | Q33516505 | ||
Provisional diagnostic criteria for depression of Alzheimer disease | Q34121328 | ||
Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants | Q34464019 | ||
Diagnostic criteria for Parkinson disease | Q34489839 | ||
What contributes to quality of life in patients with Parkinson's disease? | Q35459164 | ||
Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial | Q35485478 | ||
An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease | Q35684460 | ||
Antidepressant studies in Parkinson's disease: a review and meta-analysis | Q36008775 | ||
Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group | Q36279999 | ||
Norepinephrine: The redheaded stepchild of Parkinson's disease | Q36784705 | ||
A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease | Q36961731 | ||
A controlled trial of antidepressants in patients with Parkinson disease and depression | Q37180389 | ||
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. | Q37196231 | ||
Specific tricyclic antidepressant binding sites in rat brain | Q41752061 | ||
Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases | Q42438205 | ||
The Inventory of Depressive Symptomatology (IDS): psychometric properties. | Q42635264 | ||
Effect of reboxetine on depression in Parkinson's disease patients. | Q43986305 | ||
Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease | Q44351576 | ||
Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex | Q44418380 | ||
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study | Q46724727 | ||
Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder | Q48099054 | ||
The locus ceruleus and dementia in Parkinson's disease | Q48289979 | ||
The role of locus coeruleus in the regulation of cognitive performance | Q48301222 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Parkinson's disease | Q11085 |
atomoxetine | Q417240 | ||
P304 | page(s) | 448-455 | |
P577 | publication date | 2010-08-01 | |
2010-08-03 | |||
P1433 | published in | Neurology | Q1161692 |
P1476 | title | Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease | |
P478 | volume | 75 |
Q64864842 | Q64864842 |
Q92582730 | A Randomized Clinical Trial of Atomoxetine for Mild Cognitive Impairment in Parkinson's Disease |
Q35043846 | A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease |
Q37862761 | A précis of recent advances in the neuropsychology of mild cognitive impairment(s) in Parkinson's disease and a proposal of preliminary research criteria |
Q30240991 | A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. |
Q38571668 | Advances in the treatment of cognitive impairment in Parkinson's disease |
Q64861761 | Antidepressants for Depression, Apathy, and Gait Instability in Parkinson's Disease: A Multicenter Randomized Study |
Q43491031 | Anxiety and depression in Parkinson's disease |
Q39777480 | Apathy and Parkinson's disease |
Q39665359 | Apathy in Parkinson's disease: diagnostic and etiological dilemmas |
Q90641261 | Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis |
Q85359306 | Canadian Guidelines on Parkinson's Disease |
Q38770352 | Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system |
Q48642615 | Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia |
Q41540738 | Cognitive Function in Parkinson's Disease Patients with and without Anxiety |
Q28073680 | Cognitive Training in Parkinson's Disease: A Review of Studies from 2000 to 2014 |
Q38751099 | Cognitive decline in Parkinson disease |
Q38206496 | Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective |
Q34307633 | Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models? |
Q37364568 | Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis |
Q37968511 | Cognitive impairment in nondemented Parkinson's disease |
Q38027731 | Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment |
Q35009609 | Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis |
Q41317541 | Comprehensive treatment of dementia with Lewy bodies |
Q37971293 | Depression in Parkinson disease--epidemiology, mechanisms and management. |
Q38116807 | Depression in Parkinson's disease: identification and management |
Q38265929 | Depression in Parkinson's disease: the effectiveness and risk of pharmacotherapy. Clinical review |
Q62719741 | Depression, Apathy, Anhedonia, and Fatigue in Parkinson’s Disease |
Q37593613 | Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: the study protocol of a randomised pilot trial |
Q49126482 | Dopamine selectively remediates 'model-based' reward learning: a computational approach |
Q38067142 | Drug treatments for the neuropsychiatric complications of Parkinson's disease |
Q36010298 | DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing |
Q38875190 | Dysfunctional Sensory Modalities, Locus Coeruleus, and Basal Forebrain: Early Determinants that Promote Neuropathogenesis of Cognitive and Memory Decline and Alzheimer's Disease |
Q47319471 | Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis |
Q33765388 | Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis |
Q38797335 | Emotional manifestations of PD: Neurobiological basis |
Q47651254 | Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study. |
Q28833274 | Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study |
Q39754744 | Frontostriatal cognitive staging in Parkinson's disease |
Q47793861 | Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment |
Q35264006 | Improving response inhibition in Parkinson's disease with atomoxetine |
Q37331607 | Impulsivity and apathy in Parkinson's disease |
Q38225930 | Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies |
Q39100264 | Management of sleep disorders in Parkinson's disease and multiple system atrophy |
Q55387790 | Mild Cognitive Impairment in Parkinson's Disease-What Is It? |
Q37864573 | Mild cognitive impairment in Parkinson's disease. |
Q35165280 | Monoamine reuptake inhibitors in Parkinson's disease |
Q34135756 | Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study |
Q35028706 | Neurobiology of depression and anxiety in Parkinson's disease |
Q89736107 | Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems? |
Q38799051 | Neuropsychiatric Issues in Parkinson's Disease |
Q34089583 | Neuropsychological outcomes after psychosocial intervention for depression in Parkinson's disease |
Q39323947 | New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease |
Q38075712 | New tricks for old dogmas: optogenetic and designer receptor insights for Parkinson's disease |
Q35013240 | Noradrenaline and Parkinson's disease |
Q55004525 | Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases-An Overview of Imaging Studies. |
Q38091914 | Noradrenergic modulation of cognition: therapeutic implications |
Q38258228 | Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement |
Q38258699 | Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease |
Q34618993 | Off-label use of atomoxetine in adults: is it safe? |
Q31080551 | Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association? |
Q30239814 | Parkinson's Disease and Cognitive Impairment |
Q36351543 | Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications |
Q36186763 | Parkinson's disease dementia: a neural networks perspective |
Q35614156 | Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa |
Q33917094 | Parkinson's disease: the quintessential neuropsychiatric disorder |
Q38588201 | Psychiatric Conditions in Parkinson Disease: A Comparison With Classical Psychiatric Disorders. |
Q38206498 | Psychiatric issues in cognitive impairment |
Q38998475 | Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases |
Q91995417 | Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease |
Q38290962 | Sleep disturbances and dementia |
Q91268058 | Statistical advances in clinical trials and clinical research |
Q38070888 | Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. |
Q33784038 | Targeting impulsivity in Parkinson's disease using atomoxetine |
Q36998284 | Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. |
Q33607256 | The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease |
Q64767922 | The Neuropsychiatry of Parkinson Disease: A Perfect Storm |
Q42248817 | The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease |
Q26799352 | The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people |
Q64972290 | The pharmacologic management of depression in Parkinson's disease. |
Q35276597 | Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection |
Q38593798 | Therapy-resistant symptoms in Parkinson's disease |
Q48821094 | Treatment of Apathy in Huntington's Disease and Other Movement Disorders |
Q39342961 | Treatment of Sleep Dysfunction in Parkinson's Disease. |
Q34388686 | Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease |
Q30358337 | Treatment of psychosis and dementia in Parkinson's disease. |
Q48109363 | Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease |
Q52886915 | [Antidepressants for treatment of depression in palliative patients : a systematic literature review]. |
Q87424086 | [Coexistent depressive and anxiety disorders in neurological diseases: from a perspective of multimorbidity] |
Q27021220 | Mild cognitive impairment in Parkinson's disease. |
Search more.